Bio-Techne Co. (NASDAQ:TECH) Receives $84.63 Consensus Target Price from Brokerages

Shares of Bio-Techne Co. (NASDAQ:TECHGet Free Report) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $84.63.

A number of research analysts have recently weighed in on the company. Royal Bank of Canada cut their price objective on Bio-Techne from $85.00 to $75.00 and set a “sector perform” rating for the company in a research report on Friday, February 2nd. Stifel Nicolaus lowered shares of Bio-Techne from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a research report on Friday, February 2nd. KeyCorp cut their price objective on shares of Bio-Techne from $115.00 to $80.00 and set an “overweight” rating on the stock in a report on Wednesday, November 1st. UBS Group initiated coverage on shares of Bio-Techne in a report on Thursday, December 7th. They set a “buy” rating and a $80.00 price objective on the stock. Finally, Stephens cut their price target on shares of Bio-Techne from $92.00 to $87.00 and set an “overweight” rating on the stock in a report on Friday, February 2nd.

Get Our Latest Analysis on TECH

Bio-Techne Trading Up 0.9 %

Shares of TECH stock opened at $67.37 on Friday. Bio-Techne has a 52-week low of $51.79 and a 52-week high of $89.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.03 and a current ratio of 4.37. The firm has a market capitalization of $10.65 billion, a PE ratio of 48.82, a PEG ratio of 5.67 and a beta of 1.24. The stock has a fifty day simple moving average of $71.79 and a two-hundred day simple moving average of $71.18.

Bio-Techne Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 26th. Stockholders of record on Monday, February 12th will be paid a dividend of $0.08 per share. The ex-dividend date of this dividend is Friday, February 9th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.47%. Bio-Techne’s dividend payout ratio is currently 23.19%.

Institutional Trading of Bio-Techne

Several large investors have recently bought and sold shares of TECH. Exchange Traded Concepts LLC acquired a new stake in Bio-Techne during the 2nd quarter worth approximately $27,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Bio-Techne in the 3rd quarter valued at approximately $27,000. Harbour Investments Inc. grew its position in shares of Bio-Techne by 305.0% in the 4th quarter. Harbour Investments Inc. now owns 324 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 244 shares during the last quarter. Huntington National Bank grew its position in shares of Bio-Techne by 124.7% in the 2nd quarter. Huntington National Bank now owns 337 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 187 shares during the last quarter. Finally, Resurgent Financial Advisors LLC purchased a new position in shares of Bio-Techne in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 94.64% of the company’s stock.

About Bio-Techne

(Get Free Report

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

See Also

Analyst Recommendations for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.